Whalesbook
The Escalating Legal Barrier
The judicial machinery has intensified its scrutiny of Religare Enterprises, with a Mumbai special court for the Prevention of Money Laundering Act (PMLA) issuing summons to former Executive Chairperson Rashmi Saluja and four other key former personnel. This action marks a significant development in the Enforcement Directorate’s investigation into an alleged ₹179.54 crore money laundering scheme linked to Employee Stock Ownership Plans (ESOPs) at Care Health Insurance, an unlisted subsidiary of the firm. The court, led by Special Judge R.B. Rote, determined that prima facie evidence supports proceeding against the accused, mandating their personal appearance by June 11, 2026.
The ESOP and Takeover Nexus
At the heart of the regulatory action lies a complex web of alleged corporate misconduct. The investigation suggests that the accused allegedly orchestrated the procurement of unauthorized legal opinions to bypass regulatory objections to ESOP allotments, specifically favoring Rashmi Saluja. Furthermore, the agency has contended that this scheme was intertwined with a broader effort to frustrate the acquisition attempt by the Burman family. The ED alleges that financial inducements were provided to third parties to register bogus criminal complaints against members of the Burman family, effectively creating a defensive wall during the intense corporate power struggle that unfolded between 2023 and 2025.
The Forensic Bear Case
The persistent legal and regulatory friction surrounding Religare Enterprises poses material risks to its ongoing restructuring efforts. Beyond the current money laundering summons, the company's former leadership recently faced a significant blow from the Securities and Exchange Board of India (SEBI). In May 2026, SEBI ordered Rashmi Saluja to disgorge nearly ₹2 crore in alleged wrongful gains and imposed a ₹40 lakh penalty, concluding that she executed trades while in possession of unpublished price-sensitive information concerning the Burman Group's open offer.
Unlike better-capitalized peers in the financial services sector, Religare’s valuation is heavily pressured by this persistent governance overhang. Despite a 15% revenue increase in FY26, the company reported a sharp contraction in net profit, which fell to ₹73.16 crore, raising questions about margin sustainability during this leadership transition. The firm is currently navigating a demerger of its financial services and insurance businesses—a move designed to unlock shareholder value—yet these legal proceedings threaten to complicate the regulatory approvals necessary for such a structural split.
Outlook and Strategic Focus
While the Burman family, now the confirmed promoters, is actively infusing capital—including a recent ₹750 crore commitment—to stabilize the balance sheet and rebuild the lending business, the path to recovery remains volatile. Investors are currently weighing the potential for a fresh start against the legacy issues of the previous management team. With the stock frequently testing its 52-week lower bounds, the market remains cautious, closely monitoring whether the proposed demerger can proceed without further friction from ongoing litigation.